BHC
Price
$6.05
Change
+$0.04 (+0.67%)
Updated
Oct 17 closing price
Capitalization
2.23B
11 days until earnings call
TEVA
Price
$19.31
Change
-$0.32 (-1.63%)
Updated
Oct 17 closing price
Capitalization
22.93B
18 days until earnings call
Interact to see
Advertisement

BHC vs TEVA

Header iconBHC vs TEVA Comparison
Open Charts BHC vs TEVABanner chart's image
Bausch Health Companies
Price$6.05
Change+$0.04 (+0.67%)
Volume$1.12M
Capitalization2.23B
Teva Pharmaceutical Industries
Price$19.31
Change-$0.32 (-1.63%)
Volume$7.73M
Capitalization22.93B
BHC vs TEVA Comparison Chart in %
BHC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TEVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BHC vs. TEVA commentary
Oct 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BHC is a Hold and TEVA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 18, 2025
Stock price -- (BHC: $6.05 vs. TEVA: $19.31)
Brand notoriety: BHC and TEVA are both notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: BHC: 41% vs. TEVA: 75%
Market capitalization -- BHC: $2.23B vs. TEVA: $22.93B
BHC [@Pharmaceuticals: Generic] is valued at $2.23B. TEVA’s [@Pharmaceuticals: Generic] market capitalization is $22.93B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.85B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.96B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BHC’s FA Score shows that 0 FA rating(s) are green whileTEVA’s FA Score has 1 green FA rating(s).

  • BHC’s FA Score: 0 green, 5 red.
  • TEVA’s FA Score: 1 green, 4 red.
According to our system of comparison, TEVA is a better buy in the long-term than BHC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BHC’s TA Score shows that 3 TA indicator(s) are bullish while TEVA’s TA Score has 5 bullish TA indicator(s).

  • BHC’s TA Score: 3 bullish, 5 bearish.
  • TEVA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, TEVA is a better buy in the short-term than BHC.

Price Growth

BHC (@Pharmaceuticals: Generic) experienced а 0.00% price change this week, while TEVA (@Pharmaceuticals: Generic) price change was -3.59% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.79%. For the same industry, the average monthly price growth was +4.23%, and the average quarterly price growth was +51.45%.

Reported Earning Dates

BHC is expected to report earnings on Oct 29, 2025.

TEVA is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.79% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TEVA($22.9B) has a higher market cap than BHC($2.24B). TEVA YTD gains are higher at: -12.387 vs. BHC (-24.938). BHC has higher annual earnings (EBITDA): 3B vs. TEVA (1.9B). TEVA has more cash in the bank: 2.16B vs. BHC (1.73B). TEVA has less debt than BHC: TEVA (17.5B) vs BHC (21.7B). TEVA has higher revenues than BHC: TEVA (16.6B) vs BHC (9.86B).
BHCTEVABHC / TEVA
Capitalization2.24B22.9B10%
EBITDA3B1.9B158%
Gain YTD-24.938-12.387201%
P/E Ratio23.27N/A-
Revenue9.86B16.6B59%
Total Cash1.73B2.16B80%
Total Debt21.7B17.5B124%
FUNDAMENTALS RATINGS
BHC vs TEVA: Fundamental Ratings
BHC
TEVA
OUTLOOK RATING
1..100
6761
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
74
Overvalued
PROFIT vs RISK RATING
1..100
10042
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
9197
P/E GROWTH RATING
1..100
4510
SEASONALITY SCORE
1..100
4050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BHC's Valuation (35) in the Pharmaceuticals Other industry is somewhat better than the same rating for TEVA (74) in the Pharmaceuticals Generic industry. This means that BHC’s stock grew somewhat faster than TEVA’s over the last 12 months.

TEVA's Profit vs Risk Rating (42) in the Pharmaceuticals Generic industry is somewhat better than the same rating for BHC (100) in the Pharmaceuticals Other industry. This means that TEVA’s stock grew somewhat faster than BHC’s over the last 12 months.

TEVA's SMR Rating (100) in the Pharmaceuticals Generic industry is in the same range as BHC (100) in the Pharmaceuticals Other industry. This means that TEVA’s stock grew similarly to BHC’s over the last 12 months.

BHC's Price Growth Rating (91) in the Pharmaceuticals Other industry is in the same range as TEVA (97) in the Pharmaceuticals Generic industry. This means that BHC’s stock grew similarly to TEVA’s over the last 12 months.

TEVA's P/E Growth Rating (10) in the Pharmaceuticals Generic industry is somewhat better than the same rating for BHC (45) in the Pharmaceuticals Other industry. This means that TEVA’s stock grew somewhat faster than BHC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BHCTEVA
RSI
ODDS (%)
Bullish Trend 3 days ago
79%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
67%
Momentum
ODDS (%)
N/A
Bearish Trend 3 days ago
72%
MACD
ODDS (%)
N/A
Bearish Trend 3 days ago
73%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
77%
Bearish Trend 3 days ago
67%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
75%
Bullish Trend 3 days ago
69%
Advances
ODDS (%)
Bullish Trend about 1 month ago
75%
Bullish Trend 11 days ago
72%
Declines
ODDS (%)
Bearish Trend 3 days ago
78%
Bearish Trend 3 days ago
71%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
70%
N/A
Aroon
ODDS (%)
Bearish Trend 3 days ago
75%
Bullish Trend 3 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
BHC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TEVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
USMF51.030.27
+0.53%
WisdomTree US Multifactor
DECM32.300.06
+0.17%
FT Vest U.S. Eq Max Buffr ETF - Dec
CPII19.160.01
+0.07%
American Beacon Ionic Inflation Prot ETF
HACK85.280.04
+0.05%
Amplify Cybersecurity ETF
DGP156.89-5.84
-3.59%
DB Gold Double Long ETN

BHC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BHC has been loosely correlated with AMRX. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if BHC jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BHC
1D Price
Change %
BHC100%
+0.67%
AMRX - BHC
38%
Loosely correlated
+0.51%
AMPH - BHC
32%
Poorly correlated
+2.41%
VTRS - BHC
30%
Poorly correlated
+0.69%
TEVA - BHC
27%
Poorly correlated
-1.63%
DRRX - BHC
26%
Poorly correlated
N/A
More

TEVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, TEVA has been loosely correlated with AMRX. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if TEVA jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TEVA
1D Price
Change %
TEVA100%
-1.63%
AMRX - TEVA
41%
Loosely correlated
+0.51%
VTRS - TEVA
32%
Poorly correlated
+0.69%
ELAN - TEVA
29%
Poorly correlated
+4.39%
NBIX - TEVA
28%
Poorly correlated
+1.87%
BHC - TEVA
27%
Poorly correlated
+0.67%
More